Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Development Setbacks, Pricing Pressures Hit Top, Bottom Lines at Roche

This article was originally published in The Pink Sheet Daily

Executive Summary

"The financial crisis has arrived for the pharmaceutical industry," says CEO Severin Schwan.

You may also be interested in...

Another Phase III Study Supports Avastin Expansion To Ovarian Cancer

Adding bevacizumab to chemo in first-line and maintenance therapy gives an undisclosed benefit in progression-free survival.

Genentech Reorganization Signals Shift To New Model Under Roche

Roche’s Soriot will take over as CEO of Genentech, while key members of Genentech’s management will take on advisory roles or depart.

Roche’s High Stakes Gambit For Genentech

With Roche's unsolicited attempt to buy out Genentech's minority shareholders for $89 dollars a share, a bid totaling nearly $44 billion, the company is wagering heavily that it will not destroy one of the industry's most successful pharma-biotech collaborations. But has Roche laid out a straight flush or lost its ace to a bluff





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts